First detection of a <i>Mycobacterium tuberculosis</i> XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023.

导出 OA

翻译打印收藏纠错

作者： Inna,Friesen ^[1] ; Viola,Dreyer ^[2] ; Angela,Klingmüller ^[3] ; Sylvia,Zuber ^[4] ; Ada M,Hoffmann ^[4] ; Isabelle,Suárez ^[5] ; Beatrice,Schütz ^[4] ; Tim,Preßel ^[6] ; Sönke,Andres ^[7] ; Stefan,Niemann ^[1] ; Jan,Rybniker ^[8]

作者单位： Research Center Borstel, Leibniz Lung Center, Supranational and National Reference Center for Mycobacteria, Borstel, Germany. ^[1] German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany. ^[2] Research Center Borstel, Leibniz Lung Center, Molecular and Experimental Mycobacteriology, Borstel, Germany. ^[3] Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. ^[4] Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Medical Faculty and University Hospital of Cologne, Cologne, Germany. ^[5] Klinikum Dorsten, St. Elisabeth-Krankenhaus, Dorsten, Germany. ^[6] Eurofins MVZ Medizinisches Labor Gelsenkirchen GmbH, Eurofins GeLaMed, Gelsenkirchen, Germany. ^[7] These authors contributed equally to this work and share last authorship. ^[8] German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. ^[9] Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. ^[10]

关键词 GeneXpert I491F MDR-TB Rifampicin Ukraine XDR-TB